Pfizer Earnings

• Pfizer reports 1st quarterly loss since 2019 on weak COVID product demand

  Pfizer on Tuesday reported weak demand for its COVID vaccine and treatment, which pushed the drugmaker to its first quarterly loss since 2019.

  Health

  Oct 31, 2023
  
• Pfizer CEO says 2023 will be ‘transition year’ as it sees drop in COVID sales

  Pfizer Inc on Tuesday forecast a bigger-than-expected drop in sales of its COVID-19 vaccine and treatment for 2023, intensifying investor concerns over demand for the products.

  Money

  Jan 31, 2023
  
• Advertisement
• Pfizer forecasts higher COVID-19 vaccine, pill sales in 2022, but analysts expected more

  Pfizer raised the guidance on its anticipated vaccine and COVID-19 antiviral pill Paxlovid on Tuesday, but not as high as analysts had been expecting.

  Health

  Feb 8, 2022
• Advertisement
• Pfizer expects $29B in COVID-19 vaccine sales next year

  Pfizer's COVID-19 vaccine has become one of the most widely used inoculation in the United States and Europe, and its sales has outpaced that of its rivals.

  Money

  Nov 2, 2021
• Pfizer sees ‘durable demand’ for COVID-19 vaccine as it boosts sales forecast

  Pfizer forecast US$26 billion in COVID-19 vaccine sales this year, a more than 70 per cent jump from its last projection,

  Money

  May 4, 2021
• Pfizer expects US$15 billion in sales from coronavirus vaccine this year

  Pfizer is striving to deliver two billion doses of the vaccine in 2021 at a breakneck pace as countries rush to sign supply deals.

  Money

  Feb 2, 2021